CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients.
CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients.
复制标题
间歇性白细胞介素 2 治疗后 CD4 T 细胞的存活预示着 HIV 感染患者 CD4 T 细胞计数的增加。
DOI：
10.1086/591250
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
L
中科院分区：
文献类型：
--
作者：
Read,SarahW;Lempicki,RichardA;DiMascio,Michele;Srinivasula,Sharat;Burke,Rosanne;Sachau,William;Bosche,Marjorie;Adelsberger,JosephW;Sereti,Irini;DaveyJr,RichardT;Tavel,JorgeA;Huang,Chiung-Yu;Issaq,HaleemJ;Fox,StephenD;L
Administration of interleukin (IL)—2 to human immunodeficiency virus (HIV)—infected patients leads to significant increases in CD4 T cell counts. We previously have shown that IL-2 induces increased proliferation and survival of CD4 T cells. Deuterium labeling studies were undertaken to study the relationship between IL-2—induced increases in the CD4 T cell count and the effects of IL-2 on cell proliferation and survival. A strong inverse correlation was noted between the rate of decay of the label in CD4 cells and increases in CD4 cell counts (R= −0.67;P< .001). This correlation was not seen with the level of proliferating cells. Although the CD4 cell count at baseline and the number of CD4 cells expressing CD25 were also predictive of increases in the CD4 cell count, the rate of decay remained the most statistically significant predictor in multivariate regression models. Thus, an increase in the survival of CD4 T cells appears to be the critical mechanism leading to sustained increases in the CD4 cell counts of HIV-infected patients receiving intermittent IL-2 therapy.
